<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01943487</url>
  </required_header>
  <id_info>
    <org_study_id>905-CL-078</org_study_id>
    <secondary_id>2009-010841-29</secondary_id>
    <nct_id>NCT01943487</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Whether Verapamil Has an Effect on the Uptake and Elimination of Solifenacin and Tamsulosin When Administered in a Combination Tablet</brief_title>
  <official_title>A Phase 1, Open-label, One-sequence Study to Assess the Effect of Verapamil on the Steady State Pharmacokinetics of Solifenacin and Tamsulosin Administered as a Combination Tablet EC905 in Healthy Male Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the effect of the co-administration of verapamil on the steady-state
      pharmacokinetics (PK) of solifenacin succinate and tamsulosin given as a combination tablet,
      EC905.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effect of the co-administration of verapamil on the steady state PK of solifenacin
      succinate and tamsulosin HCl OCAS (Oral Controlled Absorption System) is evaluated in this
      study.

      Verapamil has been chosen to represent the effect of moderate CYP3A4 inhibitors on the
      combined administration of solifenacin and tamsulosin given as combination tablet EC905.

      Subjects are admitted to the clinic on Day -1. From Days 1-10, they receive one daily dose of
      EC905 to obtain steady state, followed by 20 days (Days 11-30) combined dosing of EC905 and
      verapamil.

      On Day 10 a 24-hour PK profile is obtained for solifenacin/tamsulosin. After the last dosing
      on Day 30, a post-dose 24-hour PK profile for solifenacin/tamsulosin and verapamil is
      obtained.

      Additionally, vital signs, safety ECG (Electrocardiogram) measurements, safety laboratory
      assessments, adverse events and concomitant medications are monitored throughout the
      investigational period.

      Subjects return for an ESV (End of Study Visit) 10 days after the last dosing.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of tamsulosin OCAS in plasma: AUCtau</measure>
    <time_frame>Predose, Days 1, and 7-10</time_frame>
    <description>AUCtau (area under the plasma concentration-time curve during the time interval between consecutive dosing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of solifenacin in plasma: AUCtau</measure>
    <time_frame>Predose, Days 1, and 7-10</time_frame>
    <description>AUCtau (area under the plasma concentration-time curve during the time interval between consecutive dosing)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of tamsulosin OCAS in plasma: Cmax</measure>
    <time_frame>Predose, Days 1, and 7-10</time_frame>
    <description>Cmax (maximum concentration)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of solifenacin in plasma: Cmax</measure>
    <time_frame>Predose, Days 1, and 7-10</time_frame>
    <description>Cmax (maximum concentration)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of combined doses of tamsulosin OCAS and solifenacin in steady state, and verapamil</measure>
    <time_frame>Predose, Days 27-30</time_frame>
    <description>Plasma: Ctrough (trough concentration), tmax (time to attain Cmax), CL/F (apparent total body clearance), PTR (peak trough ratio) Urine: AUCtau, Cmax, Ctrough, CL/F, tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of the interaction between combined doses of tamsulosin OCAS and solifenacin, and verapamil</measure>
    <time_frame>Screening to ESV (10 days after the last dosing)</time_frame>
    <description>AE (adverse events), clinical laboratory tests, vital signs, ECG, physical examination</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Drug-Drug Interaction (DDI)</condition>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1: verapamil + EC905</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC905</intervention_name>
    <description>Oral</description>
    <arm_group_label>1: verapamil + EC905</arm_group_label>
    <other_name>tamsulosin OCAS and solifenacin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>verapamil</intervention_name>
    <description>Oral</description>
    <arm_group_label>1: verapamil + EC905</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index between 18.5 and 30.0 kg/m2, inclusive

        Exclusion Criteria:

          -  Known or suspected hypersensitivity to EC905 or any of the components of the
             formulation used

          -  Known or suspected hypersensitivity to verapamil or any of the components of the
             formulation used

          -  Regular use of any inducer of liver metabolism (e.g. barbiturates, rifampin) in the 3
             months prior to admission to the Clinical Unit
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Chair</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SGS Aster</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrDetail_e.jsp?resultId=1062</url>
    <description>Link to Results on JAPIC</description>
  </link>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2013</study_first_submitted>
  <study_first_submitted_qc>September 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2013</study_first_posted>
  <last_update_submitted>May 29, 2014</last_update_submitted>
  <last_update_submitted_qc>May 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Verapamil</keyword>
  <keyword>Tamsulosin OCAS</keyword>
  <keyword>Solifenacin</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>EC905</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamsulosin</mesh_term>
    <mesh_term>Solifenacin Succinate</mesh_term>
    <mesh_term>Verapamil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

